The 2009 Proposed Rule for Prospective ESRD Payment: Historical Perspectives and Public Policies-Bundle Up!

American Journal of Kidney Diseases

Volumn 55, Issue 2, 2010, Pages 217-222

  Weiner, Daniel E ^a   Watnick, Suzanne G ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT; CALCITRIOL; CALCIUM ACETATE; CARNITINE; CINACALCET; DAPTOMYCIN; DOXERCALCIFEROL; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; GENTAMICIN; IRON DEXTRAN; LANTHANUM CARBONATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARICALCITOL; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; VANCOMYCIN;

BLOOD TRANSFUSION; DIALYSIS; EDITORIAL; GOVERNMENT; HEALTH CARE POLICY; HEALTH ECONOMICS; HOME DIALYSIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MEDICAID; MEDICARE; PROSPECTIVE PAYMENT; REIMBURSEMENT; UNITED STATES;

HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; PROSPECTIVE PAYMENT SYSTEM; PUBLIC POLICY; UNITED STATES;

EID: 74549195000     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.005     Document Type: Editorial

References (25)

1. Collins A.J., Foley R.N., Herzog C., et al. Excerpts from the US Renal Data System 2009 annual data report. Am J Kidney Dis 55 suppl 1 (2010) S1-S420
2. Medicare Improvements for Patients and Providers Act of 2008. Medicare, Provisions Relating to Part B, Other Payment and Coverage Improvements. Public L No. 110-275, §153(a).
3. Centers for Medicare & Medicaid Services. End-stage renal disease prospective payment system proposed rules. Fed Regist 74 187 (2009) 49922-50102
4. Nissenson A.R., Mayne T.J., and Krishnan M. The 2009 proposed rule for prospective ESRD payment: perspectives from a large dialysis organization. Am J Kidney Dis 55 2 (2010) 223-226
5. Moran J. The 2009 proposed rule for prospective ESRD payment: perspectives from a medium-sized dialysis organization. Am J Kidney Dis 55 2 (2010) 227-228
6. Sadler J.H. The 2009 proposed rule for prospective ESRD payment: perspectives from a not-for-profit small dialysis organization. Am J Kidney Dis 55 2 (2010) 229-230
7. Bhat J.G., and Bhat P. The 2009 proposed rule for prospective ESRD payment: perspectives from a for-profit small dialysis organization. Am J Kidney Dis 55 2 (2010) 231-233
8. Kristensen C., and Wish J. The 2009 proposed rule for prospective ESRD payment: perspectives from the Forum of ESRD Networks. Am J Kidney Dis 55 2 (2010) 234-236
9. Blagg C.R. The early history of dialysis for chronic renal failure in the United States: a view from Seattle. Am J Kidney Dis 49 3 (2007) 482-496
10. Rettig R.A. Origins of the Medicare kidney disease entitlement: the Social Security Amendments of 1972. In: Hanna K.E. (Ed). Biomedical Politics (1991), National Academy Press, Washington, DC 176-214
11. Rettig R., Levinsky N., and Committee for the Study of the Medicare End-Stage Renal Disease Program. Kidney Failure and the Federal Government (1991), Division of Health Care Services, Washington, DC
12. Lockridge Jr. R.S. The direction of end-stage renal disease reimbursement in the United States. Semin Dial 17 2 (2004) 125-130
13. Beusterien K.M., Nissenson A.R., Port F.K., et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7 5 (1996) 763-773
14. Evans R.W., Rader B., Manninen D.L., and Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263 6 (1990) 825-830
15. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 4 (1995) 548-554
16. Sisk J.E., Gianfrancesco F.D., and Coster J.M. Recombinant erythropoietin and Medicare payment. JAMA 266 19 (1991) 247-252
17. de Lissovoy G., Powe N.R., Griffiths R.I., et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care 32 2 (1994) 130-140
18. General Accounting Office. End Stage Renal Disease: Bundling Medicare's Payment for Drugs with Payment for all ESRD Services Would Promote Efficiency and Clinical Flexibility. US Government Accountability Office; November 2006. GAO-07-77.
19. Collins A.J., Ebben J.P., and Gilbertson D.T. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 49 1 (2007) 135-142
20. Thamer M., Zhang Y., Kaufman J., et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 15 (2007) 1667-1674
21. Steinbrook R. Medicare and erythropoietin. N Engl J Med 356 1 (2007) 4-6
22. Office of Inspector General. Medicare Reimbursement for Existing End-Stage Renal Disease Drugs (2004), US Dept of Health and Human Services OEI-03-04-00120
23. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public L No. 108-173.
24. Leavitt M.O., and US Department of Health and Human Services. Report to Congress: a design for a bundled end stage renal disease prospective payment system. Published 2008. http://www.cms.hhs.gov/ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdf Accessed November 10, 2009
25. Medicare Coverage for End-Stage Renal Disease Patients. Compilation of the Social Security laws including the Social Security Act, as amended, and related enactments through January 1, 2009. http://www.ssa.gov/OP_Home/ssact/title18/1881.htm#ft576 Accessed November 10, 2009